New Delhi: The Drugs Controller of India has intensified regulatory surveillance across the supply chain of GLP-1-based weight loss drugs, amid rising concerns over their unauthorised sale and misuse, officials said.
This move follows the recent entry of multiple generic variants of GLP-1 drugs into the Indian market, which has increased on-demand availability through retail pharmacies, online platforms, wholesalers, and wellness clinics. Authorities have flagged the risk of serious adverse health effects when these medications are used without proper medical supervision.
Taking cognisance of the issue, the national regulator, in coordination with state drug authorities, launched targeted enforcement actions to curb malpractice and prevent unauthorized distribution and promotion.
The regulator issued a comprehensive advisory to all manufacturers on March 10, 2026, explicitly prohibiting surrogate advertisements and any indirect promotional activities that could mislead consumers or encourage off-label use of the drugs.
“In recent weeks, enforcement activities have been significantly scaled up,” an official statement said.
Inspections and audits were conducted at 49 entities across multiple regions, including online pharmacy warehouses, drug wholesalers, retailers, and wellness and slimming clinics.
The inspections focused on identifying violations such as unauthorized sales without valid prescriptions, improper dispensing practices, and misleading marketing strategies. Notices have been issued to entities found in violation of regulatory norms.
The regulator reiterated that patient safety remains a top priority, warning that unsupervised use of GLP-1 drugs could lead to severe health complications. Citizens have been advised to use such medications strictly under the guidance of qualified medical practitioners.
Officials further clarified that these drugs have been approved in India with strict conditions. Their prescription is restricted primarily to endocrinologists and internal medicine specialists, and for certain indications, cardiologists.
The regulator has also warned that surveillance efforts will be further intensified in the coming weeks. Non-compliance will attract strict action, including cancellation of licenses, financial penalties, and prosecution under applicable laws, the statement added.
